Related Experiment Videos
Nitric oxide: a possible etiologic factor in spinal cord cavitation
Y Matsuyama1, K Sato, M Kamiya
1Department of Orthopaedic Surgery, Nagoya University School of Medicine, Japan.
Journal of Spinal Disorders
|July 10, 1998
Summary
Nitric oxide (NO) contributes to spinal cord cavitation after injury. Inhibiting NO with N-MMA reduced cavitation size, suggesting NO
Area of Science:
- Neuroscience
- Pathology
- Biochemistry
Background:
- Spinal cord injury can lead to cavitation, a significant pathological process.
- The role of nitric oxide (NO) in spinal cord cavitation remains unclear.
- Glial fibrillary acidic protein (GFAP) is a marker for activated astrocytes.
Purpose of the Study:
- To investigate the relationship between nitric oxide (NO) and spinal cord cavitation following injury.
- To determine if inhibiting NO affects the development of spinal cord cavities.
Main Methods:
- Mice with spinal cord injury were treated with NG-mono-methyl-L-arginine (N-MMA) to inhibit NO production.
- Spinal cord tissues were analyzed using GFAP immunostaining to assess astrocyte activation.
- Cavity size and GFAP-positive cell counts were quantified at different time points post-injury.
Main Results:
- Spinal cord cavities and GFAP-positive cells appeared concurrently 3 days after injury and enlarged by 7 days.
- N-MMA treatment significantly reduced the size of spinal cord cavities compared to controls.
- No significant difference in the number of GFAP-positive cells was observed between N-MMA treated and control groups.
Conclusions:
- Nitric oxide (NO) plays a key role in the pathogenesis of spinal cord cavitation.
- Inhibition of NO can mitigate spinal cord cavitation, offering a potential therapeutic target.
- Cavitation is primarily driven by NO released from activated glial cells, independent of astrocyte proliferation.